鄉下的妹子太便宜，一次四個都要了[12P]

stcar

good good support

dadiaoguang

谢谢

wyp5888

好图，谢谢分享。

wudaode

11

xxp13136

大家好心情

weihai

果您要查看本帖隱藏內容請

q2367975099

看看再说

金正恩

将计就计

zidantiao

真的很不错

kaifka

RESPONSE OF MICROPENIS TO TOPICAL TESTOSTERONE AND
# d8 b+ o2 M" G( C8 @GONADOTROPIN
! W6 k" F1 {' X$ Y$ TRICHARD C. KLUGO* AND JOSEPH C. CERNY
From the Division of Urology, Henry Ford Hospital, Detroit, Michigan
% [1 t; \8 q# U" k  K: \ABSTRACT
Five patients were treated with gonadotropin and topical testosterone for micropenis associated
  [) y# ?) U4 E/ m9 A. vwith hypothalamic hypogonadotropic hypogonadism. All patients received 1,000 units of gonado-
. a/ z9 U; p- ?6 C- s$ f, }7 _7 ttropin weekly for 3 weeks, with a 6-week interval followed by 10 per cent topical testosterone
+ T4 K/ N4 ?$ y* X, ]4 z0 vcream twice daily for 3 weeks. Serum testosterone levels were measured and remained equivalent
for both modes of therapy. Average penile growth response with gonadotropin was 14.3 per cent
% Y. j" f6 O! z# e3 ]increase in length and 5.0 per cent increase of girth. Topical testosterone produced an average
5 R  |. N  y' G7 `& Vincrease of 60 per cent in penile length and 52. 9 per cent in girth. The greatest growth response
) c+ Z$ ]1 [% woccurred in prepuberal male subjects with a minimal response in postpuberal male subjects. This
study suggests that 10 per cent topical testosterone cream twice daily will produce effective penile
growth. The response appears to be greater in younger children, which is consistent with previ-
0 a( x2 w2 W2 C" P8 Y0 mously published studies of age-related 5 reductase activity.
+ R+ ]" y; E/ |" ^Children with microphallus regardless of its etiology will
% R! T: F( `$ Rrequire augmentation or consideration for alteration of exter-
nal genitalia. In many instances urethroplasty for hypo-
# J/ `! w5 p) H- r" qspadias is easier with previous stimulation of phallic growth.
6 I2 W! r1 a* u* g& T0 m) a3 yThe use of testosterone administered parenterally or topically
has produced effective phallic growth. 1- 3 The mechanism of
response has been considered as local or systemic. With this
in mind we studied 5 children with microphallus for response
to gonadotropin and to topical testosterone independently.
MATERIALS AND METHODS
Five 46 XY male subjects between 3 and 17 years old were
evaluated for serum testosterone levels and hypothalamic
# k  y+ ]2 P3 Q3 T4 Xfunction. Of these 5 boys 2 were considered to have Kallmann's
syndrome, 1 Prader-Willi syndrome and 2 idiopathic hypotha-
8 D9 O- I! T- p+ Alamic deficiency. After evaluation of response to luteinizing
4 b4 [/ f% E% Mhormone-releasing hormone these patients were treated with
) U4 j# r6 e' v/ r& P' K1,000 units of gonadotropin weekly for 3 weeks. Six weeks
) \0 @% `7 J$ ?8 n* x' I6 Eafter completion of gonadotropin therapy 10 per cent topical
testosterone was applied to the phallus twice daily for 3 weeks.
Serum testosterone, luteinizing hormone and follicle-stimulat-
  R, J: Q6 o8 v3 k; Eing hormone were monitored before, during and after comple-
tion of each phase of therapy. Penile stretch length was
' [! b" m( [1 r' w+ ^1 Nobtained by measuring from the symphysis pubis to the tip of
the glans. Penile circumferential (girth) measurements were
obtained using an orthopedic digital measuring device (see
6 \  j3 J0 S& z; i$ Z( gfigure).
RESULTS
% c" ]) c/ S& }( r/ k7 q6 E( bSerum testosterone increased moderately to levels between
) f) M2 T6 {( ?: F8 J% A; |5 n* E50 and 86 ng./dl. with gonadotropin stimulation. Serum testos-
" ~- c3 k/ b% x9 Q. j" Eterone levels with topical testosterone remained near pre-
treatment levels (35 ng./dl.) or were elevated to similar levels
2 ?" q! \5 N# K, \7 c3 K& s  ddeveloped after gonadotropin therapy (96 ng./dl.). Higher
serum levels were noted in older patients (12 and 17 years old),
while lower levels persisted in younger patients (4, 8, and 10
years old) (see table). Despite absence of profound alterations
of serum testosterone the topical therapy provided a greater
Accepted for publication July 1, 1977. ·
: r( z; r. ~" FRead at annual meeting of American Urological Association,
7 w. T1 O& t6 j. TChicago, Illinois, April 24-28, 1977.
6 v& F! ~- {, N* N* t, x7 h( g* Requests for reprints: Division of Urology, Henry Ford Hospital,
2799 W. Grand Blvd., Detroit, Michigan 48202.
- ^& J+ m! f# W. l" iimprovement in phallic growth compared to gonadotropin.
9 p$ q- \1 r$ ?+ y8 [9 z$ `Average phallic growth with gonadotropin was 14.3 per cent
5 \6 j6 ]* q- U( yincrease in length and 5.0 per cent increase of girth. Topical
( @$ t9 @- }5 G  ^6 ]testosterone produced a 60.0 per cent increase of phallic length
$ a" O& I. u* @" ?+ ]4 L1 ]/ Xand 52.9 per cent increase of girth (circumference). The
response to topical testosterone was greatest in children be-
3 M0 c5 c0 N8 F* c9 A/ e: Z( ntween 4 and 8 years old, with a gradual decrease to age 17
; [9 g! y2 m( c" S) gyears (see table).
9 e2 t6 m# o7 f4 v( u0 Y. BDISCUSSION
Topical testosterone has been used effectively by other
) w+ X3 n1 e  }4 Wclinicians but its mode of action remains controversial. Im-
mergut and associates reported an excellent growth response
to topical testosterone with low levels of serum testosterone,
& a& w+ ~7 s5 ^8 H$ t0 |7 nsuggesting a local effect.1 Others have obtained growth re-
sponse with high. levels of serum testosterone after topical
1 }3 m. ^/ F7 E- T4 vadministration, suggesting a systemic response. 3 The use of
/ s- S# H' a* wgonadotropin to obtain levels of serum testosterone compara-
ble to levels obtained with topical testosterone would seem to
& S# e" h  G& W6 Pprovide a means to compare the relative effectiveness of
0 q3 I* _* q& ?: o: C% Itopical testosterone to systemic testosterone effect. It cer-
tainly has been established that gonadotropin as well as par-
enteral testosterone administration will produce genital
growth. Our report shows that the growth of the phallus was
significantly greater with topical applications than with go-
nadotropin, particularly in children less than 10 years old.
The levels of serum testosterone remained similar or lower
than with gonadotropin during therapy, suggesting that topi-
cal application produces genital growth by its local effect as
. K% p% }& m, a% b5 Awell as its systemic effect.
Review of our patients and their growth response related to
age shows a greater growth response at an earlier age. This is
consistent with the findings of Wilson and Walker, who
reported an increased conversion of testosterone to dihydrotes-
  y7 S& E( z1 H6 utosterone in the foreskin of neonates and infants.4 This activ-
ity gradually decreases with age until puberty when it ap-
# a6 `. Y/ j$ J! L/ n: Q: Jproaches the same level of activity as peripheral skin. It may
well be that absorption of testosterone is less when applied at
* d/ D$ y9 V4 i; Pan earlier age as suggested by lower serum levels in children
less than 10 years old. This fact may be explained by the
' c9 P0 R8 `1 s6 |greater ability of phallic skin to convert testosterone to dihy-
# @1 J4 A: B+ R. f7 sdrotestosterone at this age. Conversely, serum levels in older
patients were higher, possibly because of decreased local
667
668 KLUGO AND CERNY
( V9 Z( n- ]6 a3 w3 K& r7 UPt. Age
(yrs.)
Serum Testosterone Phallus (cm.) Change Length
(ng./dl.) Girth x Length (%)
( @$ I5 c, l" y4
; F1 L3 ?2 A/ |! `) z8
) f- J# ~+ M3 Q( _, A% c10
12
17
, b4 V8 z& `( h7 ?, h3 }Gonadotropin
71.6 2.0 X 3 16.6
50.4 4.0 X 5.0 20.0
22.0 4.5 X 4.0 25.0
5 s% b4 q$ M) w. g8 @84.6 4.0 X 4.5 11.1
+ u# O3 f) l2 w85.9 4.5 X 5.5 9.0
Av. 14.3
3 m9 K# X: V& F4
, F" W  D* i) J8
+ J3 _* ?. _1 i7 L9 M) O10
12
7 y4 Q' L8 R; Y: B; ?: x17
Topical testosterone
34.6 4.5 X 6.5 85
( N4 o8 E1 F% {) @' v# ^- O" h38.8 6.0 X 8.5 70
40.0 6.0 X 6.5 62.5
! C( k- Q$ i' _. W* w' i/ t% k93.6 6.0 X 7.0 55.5
95.0 6.5 X 7.0 27.2
: y9 \  X4 z" @! o' u4 tAv. 60.0
available testosterone. Again, emphasis should be placed on
+ `4 I6 a' \0 D" v* Z. [" e) z+ Kearly therapy when lower levels of testosterone appear to
provide the best responses. The earlier therapy is instituted
the more likely there will be an excellent response with low
serum levels. Response occurs throughout adolescence as
noted in nomograms of phallic growth. 7 The actual response
to a given serum level of testosterone is much greater at birth
7 r9 Y; V0 {: qand gradually decreases as boys reach puberty. This is most
likely related to the conversion of testosterone to dihydrotes-
tosterone and correlates well with the studies of testosterone
* I! [6 R. D, C' R2 O, \conversion in foreskin at various ages.
The question arises regarding early treatment as to whether
* v2 W- S# f; @$ ione might sacrifice ultimate potential growth as with acceler-
ated bone growth. The situation appears quite the reverse
with phallic response. If the early growth period is not used
- Z5 ?  u4 [' A4 mwhen 5a reductase activity is greatest then potential growth
( X: G& I% B$ _may be lost. We have not observed any regression of growth
attained with topical or gonadotropin therapy. It may well
* p$ ~9 {8 u8 A0 ], Kbe that some patients will show little or no response to any
, s. U0 F8 d  O# O+ fform of therapy. This would suggest a defect in the ability to
+ l+ S- V. d7 w) Y, Z9 Qconvert testosterone to dihydrotestosterone and indicate that
' r- K8 u7 k9 B6 ~3 d5 Sphallic and peripheral skin, and subcutaneous tissue should
be compared for 5a reductase activity.
) Q0 e0 y# `# _7 DA, loop enlarges to measure penile girth in millimeters. B,
example of penile girth computed easily and accurately.
2 b/ V2 I" I/ ^2 Kconversion of testosterone to dihydrotestosterone. It is in this
0 b$ j* A: t! P7 r' jolder group that others have noted high levels of serum
+ k+ ~' Z7 @, d# M" V6 Q0 R, y/ @testosterone with topical application. It would also appear
" I% O* w& b. H9 t5 g) ^that phallic response during puberty is related directly to the
serum testosterone level. There also is other evidence of local
# L# ^' j2 N' h& ^, ~$ Sresponse to testosterone with hair growth and with spermato-
genesis. 5• 6
Administration of larger doses of gonadotropin or systemic
* e) b* h# [/ v4 b1 Etestosterone, as well as topical applications that produce
higher levels of serum testosterone (150 to 900 ng./dl.), will
also produce phallic growth but risks accelerated skeletal
maturation even after stopping treatment. It would appear
that this may be avoided by topical applications of testosterone
* w( o3 X' ~* H; ^$ I. W1 Kand monitoring of serum testosterone. Even with this control
( K: j4 k! k& u0 x/ F  U4 tthe duration of our therapy did not exceed 3 weeks at any
1 [# m% g0 ]- U. H3 etime. It is apparent that the prepuberal male subject may
suffer accelerated bone growth with testosterone levels near
" j/ E+ q0 L* Y% `- q200 ng./dl. When skeletal maturation is complete the level of
serum testosterone can be maintained in the 700 to 1,300 ng./
, R6 A* F4 _" C2 p4 Q& L- Z4 E+ j" Ddl. range to stimulate phallic growth and secondary sexual
/ |# g+ H) {! n: s# B8 I8 Dchanges. Therefore, after skeletal maturation parenteral tes-
# J* Z$ H8 w- x0 V2 Wtosterone may be used to advantage. Before skeletal matura-
tion care must be taken to avoid maintaining levels of serum
1 D" [4 v1 M/ {7 q) Ktestosterone more than 100 ng./dl. Low-dose gonadotropin
' m' X/ s" d' u9 c' tdepends upon intrinsic testicular activity and may require
5 ~( f- U5 N* h+ R4 h4 @prolonged administration for any response.
Alternately, topical testosterone does not depend upon tes-
/ d2 K& u5 X. p# S$ T+ K% Sticular function and may provide a more constant level of
' V7 g2 d5 e3 M% |. |3 [# qREFERENCES
& H/ a1 ]$ U, ]5 a1. Immergut, M., Boldus, R., Yannone, E., Bunge, R. and Flocks,
) k1 G( k( _, O: ER.: The local application of testosterone cream to the prepub-
8 B* Y3 a- O* q  C* l. _ertal phallus. J. Urol., 105: 905, 1971.
2. Guthrie, R. D., Smith, D. W. and Graham, C. B.: Testosterone
treatment for micropenis during early childhood. J. Pediat.,
83: 247, 1973.
3. Jacobs, S. C., Kaplan, G. W. and Gittes, R. F.: Topical testoster-
one therapy for penile growth. Urology, 6: 708, 1975.
" w4 U# s. L. f' V2 a) }  V4. Wilson, J. D. and Walker, J. D.: The conversion of testosterone
to 5 alpha-androstan-17 beta-01-3-one (dihydrotestosterone) by
9 N) B' H& `8 ]! `" p. Q3 Lskin slices of man. J. Clin. Invest., 48: 371, 1969.
0 V8 i/ a& g( y% }5. Papa, C. M. and Klingman, A. M.: Stimulation of hair growth
by topical application of androgens. J.A.M.A., 191: 521, 1965.
6. Gittes, R. F., Smith, G., Conn, C. A. and Smith, F.: Local
$ [* V5 A+ M! h* T- g3 Y9 Yandrogenic effect of interstitial cell tumor of the testis. J.
" j# |# f  G  K( M: m. j# \9 @# ]Urol., 104: 774, 1970.
& h* \; s8 r0 @* e6 A. L. N) Q7. Schonfeld, W. A. and Beebe, G. W.: Normal growth and varia-
& z1 p% ^( W3 _% M* ction in the male genitalia from birth to maturity. J. Urol., 48: